EP3256140 - COMPOSITIONS FOR EBOLA VIRUS VACCINATION [Right-click to bookmark this link] | |||
Former [2017/51] | METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION | ||
[2019/43] | Status | No opposition filed within time limit Status updated on 12.02.2021 Database last updated on 22.08.2024 | |
Former | The patent has been granted Status updated on 28.02.2020 | ||
Former | Grant of patent is intended Status updated on 08.01.2020 | ||
Former | Request for examination was made Status updated on 04.11.2019 | ||
Former | Grant of patent is intended Status updated on 10.10.2019 | ||
Former | Request for examination was made Status updated on 17.11.2017 | ||
Former | The international publication has been made Status updated on 06.07.2017 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Etubics Corporation 410 West Harrison Street, Suite 200 Seattle WA 98119 / US | [2017/51] | Inventor(s) | 01 /
JONES, Frank R. 410 West Harrison Street Suite 200 Seattle, Washington 98119 / US | 02 /
GABITZSCH, Elizabeth 410 West Harrison Street Suite 200 Seattle, Washington 98119 / US | [2018/01] |
Former [2017/51] | 01 /
JONES, Frank R. 1124 Columbia Street Seattle, Washington 98104 / US | ||
02 /
GABITZSCH, Elizabeth 1124 Columbia Street Seattle, Washington 98104 / US | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
Former [2020/14] | J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
Former [2017/51] | J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 16735409.1 | 07.01.2016 | [2017/51] | WO2016US12482 | Priority number, date | US201562101968P | 09.01.2015 Original published format: US 201562101968 P | [2017/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016112188 | Date: | 14.07.2016 | Language: | EN | [2016/28] | Type: | A1 Application with search report | No.: | EP3256140 | Date: | 20.12.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.07.2016 takes the place of the publication of the European patent application. | [2017/51] | Type: | B1 Patent specification | No.: | EP3256140 | Date: | 01.04.2020 | Language: | EN | [2020/14] | Search report(s) | International search report - published on: | AU | 14.07.2016 | (Supplementary) European search report - dispatched on: | EP | 20.06.2018 | Classification | IPC: | A61K35/761, A61K39/12, A61P31/14 | [2017/51] | CPC: |
A61K39/12 (EP,KR,US);
A61K35/761 (US);
A61K38/19 (EP,KR,US);
A61P31/14 (EP);
C12N15/861 (US);
A61K2300/00 (KR);
C12N2710/10043 (EP,KR,US);
C12N2710/10341 (US);
C12N2760/14122 (US);
| C-Set: |
A61K38/19, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/51] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | ZUSAMMENSETZUNGEN FÜR EBOLA-VIRUS-IMPFSTOFF | [2019/43] | English: | COMPOSITIONS FOR EBOLA VIRUS VACCINATION | [2019/43] | French: | COMPOSITIONS POUR LA VACCINATION CONTRE LE VIRUS EBOLA | [2019/43] |
Former [2017/51] | VERFAHREN UND ZUSAMMENSETZUNGEN FÜR EBOLA-VIRUS-IMPFSTOFF | ||
Former [2017/51] | METHODS AND COMPOSITIONS FOR EBOLA VIRUS VACCINATION | ||
Former [2017/51] | MÉTHODES ET COMPOSITIONS POUR LA VACCINATION CONTRE LE VIRUS EBOLA | Entry into regional phase | 05.07.2017 | National basic fee paid | 05.07.2017 | Search fee paid | 05.07.2017 | Designation fee(s) paid | 05.07.2017 | Examination fee paid | Examination procedure | 05.07.2017 | Examination requested [2017/51] | 05.07.2017 | Date on which the examining division has become responsible | 10.01.2019 | Amendment by applicant (claims and/or description) | 11.10.2019 | Communication of intention to grant the patent | 31.10.2019 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 09.01.2020 | Communication of intention to grant the patent | 19.02.2020 | Fee for grant paid | 19.02.2020 | Fee for publishing/printing paid | 19.02.2020 | Receipt of the translation of the claim(s) | Opposition(s) | 12.01.2021 | No opposition filed within time limit [2021/11] | Fees paid | Renewal fee | 29.01.2018 | Renewal fee patent year 03 | 22.01.2019 | Renewal fee patent year 04 | 23.01.2020 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 07.01.2016 | AL | 01.04.2020 | AT | 01.04.2020 | CY | 01.04.2020 | CZ | 01.04.2020 | DK | 01.04.2020 | EE | 01.04.2020 | FI | 01.04.2020 | HR | 01.04.2020 | LT | 01.04.2020 | LV | 01.04.2020 | MC | 01.04.2020 | MK | 01.04.2020 | NL | 01.04.2020 | PL | 01.04.2020 | RO | 01.04.2020 | RS | 01.04.2020 | SE | 01.04.2020 | SI | 01.04.2020 | SK | 01.04.2020 | SM | 01.04.2020 | TR | 01.04.2020 | BG | 01.07.2020 | NO | 01.07.2020 | GR | 02.07.2020 | IS | 01.08.2020 | PT | 17.08.2020 | LU | 07.01.2021 | [2024/29] |
Former [2024/22] | HU | 07.01.2016 | |
AL | 01.04.2020 | ||
AT | 01.04.2020 | ||
CY | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
MC | 01.04.2020 | ||
MK | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SI | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
LU | 07.01.2021 | ||
Former [2023/33] | HU | 07.01.2016 | |
AL | 01.04.2020 | ||
AT | 01.04.2020 | ||
CY | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
MC | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SI | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
LU | 07.01.2021 | ||
Former [2023/30] | AL | 01.04.2020 | |
AT | 01.04.2020 | ||
CY | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
MC | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SI | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
LU | 07.01.2021 | ||
Former [2021/43] | AL | 01.04.2020 | |
AT | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
MC | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SI | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
LU | 07.01.2021 | ||
Former [2021/40] | AL | 01.04.2020 | |
AT | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
MC | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SI | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2021/24] | AL | 01.04.2020 | |
AT | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SI | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2021/10] | AL | 01.04.2020 | |
AT | 01.04.2020 | ||
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
EE | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
NL | 01.04.2020 | ||
PL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SK | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2021/08] | AL | 01.04.2020 | |
CZ | 01.04.2020 | ||
DK | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
NL | 01.04.2020 | ||
RO | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
SM | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2021/04] | AL | 01.04.2020 | |
CZ | 01.04.2020 | ||
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
NL | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2020/51] | CZ | 01.04.2020 | |
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
NL | 01.04.2020 | ||
RS | 01.04.2020 | ||
SE | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2020/50] | CZ | 01.04.2020 | |
FI | 01.04.2020 | ||
HR | 01.04.2020 | ||
LT | 01.04.2020 | ||
LV | 01.04.2020 | ||
NL | 01.04.2020 | ||
SE | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
GR | 02.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2020/49] | CZ | 01.04.2020 | |
FI | 01.04.2020 | ||
LT | 01.04.2020 | ||
NL | 01.04.2020 | ||
SE | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2020/48] | FI | 01.04.2020 | |
LT | 01.04.2020 | ||
NL | 01.04.2020 | ||
SE | 01.04.2020 | ||
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
IS | 01.08.2020 | ||
PT | 17.08.2020 | ||
Former [2020/47] | LT | 01.04.2020 | |
BG | 01.07.2020 | ||
NO | 01.07.2020 | ||
IS | 01.08.2020 | ||
Former [2020/46] | BG | 01.07.2020 | |
IS | 01.08.2020 | ||
Former [2020/39] | BG | 01.07.2020 | Documents cited: | Search | [Y]US2013224144 (BALINT JOSEPH P [US], et al) [Y] 1-15 * page 35, line 14; examples 2-4; claim 1 *; | [Y]WO2014031178 (ETUBICS CORP [US], et al) [Y] 1-15 * paragraph [0068]; examples 1-4 *; | [Y] - FRANK R JONES ET AL, "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 40, doi:10.1016/J.VACCINE.2011.07.073, ISSN 0264-410X, (20110710), pages 7020 - 7026, (20110727), XP028283453 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1016/j.vaccine.2011.07.073 | [Y] - GABITZSCH E S ET AL, "A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 122, no. 1, doi:10.1016/J.IMLET.2008.11.003, ISSN 0165-2478, (20090129), pages 44 - 51, (20081213), XP025935768 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1016/j.imlet.2008.11.003 | [Y] - LEDGERWOOD ET AL., "A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 2, ISSN 0264-410X, (20101027), pages 304 - 313, (20101027), XP027539091 [Y] 1-15 * abstract; page 305, column right, paragraph 4 * | International search | [A]WO2006033672 (UNIV PENNSYLVANIA [US], et al) [A] 1-138* See Whole Document *; | [X]US2013224144 (BALINT JOSEPH P [US], et al) [X] 1-138 * see [0058], [0110-0112] and Examples *; | [X]WO2014031178 (ETUBICS CORP [US], et al) [X] 1-138 * see [0084-0085], [00144] and [00146], pp. 43-45, Examples and Claims *; | [X] - JONES, F. et al., "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine''.", Vaccine, (20110000), vol. 29, no. 40, doi:doi:10.1016/j.vaccine.2011.07.073, pages 7020 - 7026, XP 028283453 [X] 1-138 * see Discussion * | [X] - GABITZSCH, E. et al., "A Preliminary and Comparative Evaluation of a Novel Ad5 [E1-, Eb2-] Recombinant Based Vaccine Used to Induce Cell Mediated Immune Responses''.", Immunol. Lett., (20090000), vol. 122, no. 1, doi:doi:10.1016/j.imlet.2008.11.003, pages 44 - 51, XP025935768 [X] 1-138 * see Summary, Introduction and Discussion * DOI: http://dx.doi.org/10.1016/j.imlet.2008.11.003 | [A] - LEDGERWOOD, J. et al., "A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults''.", Vaccine, (20110000), vol. 29, pages 304 - 313, XP 027539091 [A] 1-138 * see Whole Document * | [A] - HOENEN, T. et al., "Current Ebola Vaccines", Expert Opin. Biol. Ther., (20120000), vol. 12, no. 7, doi:doi:10.1517/14712598.2012.685152, pages 859 - 872, XP 002731403 [A] 1-138 * see Whole Document * |